NASDAQ:OBIO - Nasdaq - US68572M1062 - Common Stock - Currency: USD
2.46
+0.04 (+1.65%)
The current stock price of OBIO is 2.46 USD. In the past month the price decreased by -11.83%. In the past year, price decreased by -47.77%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.02 | 232.31B | ||
ISRG | INTUITIVE SURGICAL INC | 70.18 | 192.17B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.81 | 155.01B | ||
SYK | STRYKER CORP | 30.65 | 146.59B | ||
MDT | MEDTRONIC PLC | 15.57 | 106.66B | ||
BDX | BECTON DICKINSON AND CO | 11.86 | 47.99B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.86 | 44.12B | ||
IDXX | IDEXX LABORATORIES INC | 42.69 | 39.43B | ||
RMD | RESMED INC | 26.95 | 35.88B | ||
DXCM | DEXCOM INC | 50.52 | 32.68B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 14.96 | 31.51B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.41 | 22.46B |
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. The company is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The company is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
ORCHESTRA BIOMED HOLDINGS IN
150 Union Square Drive
New Hope PENNSYLVANIA US
Employees: 56
Phone: 16463439298
The current stock price of OBIO is 2.46 USD. The price increased by 1.65% in the last trading session.
The exchange symbol of ORCHESTRA BIOMED HOLDINGS IN is OBIO and it is listed on the Nasdaq exchange.
OBIO stock is listed on the Nasdaq exchange.
13 analysts have analysed OBIO and the average price target is 15.15 USD. This implies a price increase of 516.02% is expected in the next year compared to the current price of 2.46. Check the ORCHESTRA BIOMED HOLDINGS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a market capitalization of 94.24M USD. This makes OBIO a Micro Cap stock.
ORCHESTRA BIOMED HOLDINGS IN (OBIO) currently has 56 employees.
ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a resistance level at 2.62. Check the full technical report for a detailed analysis of OBIO support and resistance levels.
The Revenue of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is expected to decline by -11.18% in the next year. Check the estimates tab for more information on the OBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OBIO does not pay a dividend.
ORCHESTRA BIOMED HOLDINGS IN (OBIO) will report earnings on 2025-05-09, after the market close.
ORCHESTRA BIOMED HOLDINGS IN (OBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
The outstanding short interest for ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 2.16% of its float. Check the ownership tab for more information on the OBIO short interest.
ChartMill assigns a fundamental rating of 2 / 10 to OBIO. OBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months OBIO reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -10.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -80.11% | ||
ROE | -185.16% | ||
Debt/Equity | 0.43 |
ChartMill assigns a Buy % Consensus number of 85% to OBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -22.12% and a revenue growth -11.18% for OBIO